Other languages Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
2.54 ^USD	+7.63%		+12.89%	+30.93%

02:10pm	Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $3,000	MT
Mar. 04	North American Morning Briefing : Stock Futures -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	03:56pm
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	01:34pm
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08:06am
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	Feb. 13
MaxCyte's strategic platform licences redeem otherwise modest results	Jan. 09
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress	23-10-31
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform	23-09-11
Insider Sell: Lyell Immunopharma	23-08-17
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
MaxCyte Signs Strategic Platform License with Lyell Immunopharma	23-07-06
MaxCyte inks strategic platform license with Lyell Immunopharma	23-07-06
Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer	23-07-05
Lyell Immunopharma, Inc. Announce Resignation of Rahsaan Thompson as the Chief Legal Officer	23-06-06
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
Lyell Immunopharma, Inc. Appoints Lynn Seely as CEO	22-12-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Other languages

Filters